Literature DB >> 9394890

Risk factors for acquired megaesophagus in dogs.

A R Gaynor1, F S Shofer, R J Washabau.   

Abstract

OBJECTIVE: To identify risk factors associated with acquired megaesophagus in dogs.
DESIGN: Case-control study. ANIMALS: 136 dogs with acquired megaesophagus (case dogs); 272 dogs from the general hospital population and 151 dogs that underwent thyroid-stimulating hormone response tests (control dogs). All dogs were more than 6 months old. PROCEDURE: Medical records of dogs in which megaesophagus was diagnosed during a 10-year period were reviewed. Inclusion criteria included regurgitation or vomiting, onset of clinical signs at more than 6 months of age, and radiographic evidence of generalized esophageal dilatation. Dogs with intra- or extraesophageal obstructive disease, brain stem disease, or neck trauma were excluded from analyses. Statistical analyses included odds ratios, 95% confidence intervals, and two-tailed t-tests. Control dogs were frequency matched to case dogs on the basis of year of diagnosis.
RESULTS: Dogs with megaesophagus ranged from 0.75 to 18 years old (mean, 8.1 years) and were significantly older and heavier than control dogs. More males than females were affected, but sex and reproductive status were not associated with megaesophagus. German Shepherd Dogs, Golden Retrievers, and Irish Setters were at increased risk for developing megaesophagus. Peripheral neuropathies, laryngeal paralysis, acquired myasthenia gravis, esophagitis, and chronic or recurrent gastric dilatation with or without volvulus were associated with an increased risk of developing megaesophagus. Hypothyroidism was not associated with megaesophagus. CLINICAL IMPLICATIONS: Dogs with acquired megaesophagus should be evaluated for peripheral neuropathies, laryngeal paralysis, acquired myasthenia gravis, esophagitis, and chronic or recurrent gastric dilatation with or without volvulus. These dogs may be evaluated for hypothyroidism; however, this study did not reveal a clear association between hypothyroidism and acquired megaesophagus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394890

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Resolution of esophageal dysmotility following treatment of nasal disease in a dog.

Authors:  Laura Harjes; Helene Le Pommellet; Eric Hostnik; Adam Rudinsky
Journal:  Can Vet J       Date:  2018-02       Impact factor: 1.008

2.  Glossitis in an older non-corgi dog: Diagnosis and long-term follow-up.

Authors:  Lucinda R Krenzke; Starr Cameron; Jessica C Pritchard; D Blake Webb; Ling T Guo; G Diane Shelton
Journal:  Can Vet J       Date:  2022-08       Impact factor: 1.075

3.  Long-term management of a dog with idiopathic megaesophagus and recurrent aspiration pneumonia by use of an indwelling esophagostomy tube for suction of esophageal content and esophagogastric tube feeding.

Authors:  Yuka Kanemoto; Kenjiro Fukushima; Hideyuki Kanemoto; Koichi Ohno; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2016-11-17       Impact factor: 1.267

4.  A case-control study to identify risk factors for adult-onset idiopathic megaoesophagus in Australian dogs, 2017-2018.

Authors:  M Renwick; M A Stevenson; A Wiethoelter; C Mansfield
Journal:  BMC Vet Res       Date:  2020-05-24       Impact factor: 2.741

Review 5.  Emesis in dogs: a review.

Authors:  C Elwood; P Devauchelle; J Elliott; V Freiche; A J German; M Gualtieri; E Hall; E den Hertog; R Neiger; D Peeters; X Roura; K Savary-Bataille
Journal:  J Small Anim Pract       Date:  2010-01       Impact factor: 1.522

6.  Laparoscopic repositioning of chronic gastric volvulus in a dog.

Authors:  Frans G Van Heerden; Marthinus J Hartman; Vanessa McClure; Robert M Kirberger
Journal:  J S Afr Vet Assoc       Date:  2018-11-06       Impact factor: 1.474

7.  Videofluoroscopic swallow study features of lower esophageal sphincter achalasia-like syndrome in dogs.

Authors:  Megan E Grobman; James Schachtel; C Prakash Gyawali; Teresa E Lever; Carol R Reinero
Journal:  J Vet Intern Med       Date:  2019-08-05       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.